NASDAQ$LFST
LifeStance Health Group Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
LifeStance's Q2 2023 financial performance reflected revenue growth driven by clinician growth and increased visit volumes, but was offset by increased expenses.
LifeStance Health Group reported a 24% increase in total revenue to $259.6 million for Q2 2023. The company's net loss was $45.5 million, driven by stock-based compensation expense. The company is raising full year revenue and Center Margin guidance, with the following outlook for 2023: expects full year revenue of $1.01 to $1.04 billion, Center Margin of $280 to $300 million, and Adjusted EBITDA of $50 to $62 million.
- Total revenue increased 24% to $259.6 million.
- Total clinicians reached 6,132, up 17% year-over-year.
- Net loss was $45.5 million, compared to a net loss of $68.7 million in the prior year.
- Adjusted EBITDA decreased 3% to $14.1 million.
Headline financials
Revenue & EPS history
LifeStance · Revenue · Quarterly
$260M
Forward guidance
LifeStance is raising full year revenue and Center Margin guidance, with the following outlook for 2023: expects full year revenue of $1.01 to $1.04 billion, Center Margin of $280 to $300 million, and Adjusted EBITDA of $50 to $62 million. For the third quarter of 2023, the Company expects total revenue of $250 to $260 million, Center Margin of $69 to $76 million, and Adjusted EBITDA of $11 to $17 million.
Tailwinds
- Expecting full year 2023 revenue of $1.01 to $1.04 billion
- Expecting Center Margin of $280 to $300 million
- Reaffirming full year 2023 Adjusted EBITDA guidance of $50 to $62 million
- Expecting total revenue of $250 to $260 million for Q3 2023
- Expecting Center Margin of $69 to $76 million for Q3 2023
Headwinds
- Expecting Adjusted EBITDA of $11 to $17 million for Q3 2023
- We may not grow at the rates we historically have achieved or at all
- If we fail to manage our growth effectively, our expenses could increase more than expected
- Our ability to recruit new clinicians and retain existing clinicians is a risk
- If reimbursement rates paid by third-party payors are reduced our business could be harmed
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
-4.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.2%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+24.6%
Q4 2023
Best reaction
-49.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +19.8% | +7.7% | +0.5% | |
| Q4 2025 | +4.3% | +0.0% | -11.5% | |
| Q3 2025 | -3.6% | +29.1% | +30.1% | |
| Q1 2025 | -16.0% | -10.7% | -10.8% | |
| Q4 2024 | +3.1% | +6.8% | -10.8% | |
| Q3 2024 | +3.2% | +3.8% | +2.9% | |
| Q2 2024 | +1.6% | +6.0% | +26.1% | |
| Q1 2024 | -1.7% | +5.9% | -19.1% | |
| Q4 2023 | +24.6% | +21.8% | -3.4% | |
| Q3 2023 | -9.4% | -8.9% | +7.9% | |
| Q2 2023 | -5.0% | -7.4% | -17.1% | |
| Q1 2023 | -1.4% | +1.1% | +1.7% | |
| Q4 2022 | +22.2% | +23.8% | +65.6% | |
| Q3 2022 | -30.4% | -15.9% | -23.0% | |
| Q2 2022 | +6.2% | +10.8% | +29.3% | |
| Q1 2022 | -13.9% | +0.4% | +10.1% | |
| Q4 2021 | -12.7% | -5.9% | +4.2% | |
| Q3 2021 | -27.3% | -22.8% | -29.1% | |
| Q2 2021 | -49.7% | -40.6% | -30.2% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro